Barclays PLC grew its position in Humacyte, Inc. (NASDAQ:HUMA - Free Report) by 177.6% during the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 236,742 shares of the company's stock after acquiring an additional 151,458 shares during the quarter. Barclays PLC owned 0.19% of Humacyte worth $1,288,000 as of its most recent filing with the Securities and Exchange Commission (SEC).
Other large investors have also added to or reduced their stakes in the company. Renaissance Technologies LLC increased its stake in Humacyte by 693.0% in the 2nd quarter. Renaissance Technologies LLC now owns 600,300 shares of the company's stock worth $2,881,000 after acquiring an additional 524,600 shares during the last quarter. State Street Corp increased its stake in Humacyte by 66.1% in the 3rd quarter. State Street Corp now owns 4,764,155 shares of the company's stock worth $25,917,000 after acquiring an additional 1,895,529 shares during the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC bought a new stake in Humacyte in the 3rd quarter worth approximately $596,000. Thrivent Financial for Lutherans bought a new stake in Humacyte in the 3rd quarter worth approximately $712,000. Finally, Millennium Management LLC increased its stake in Humacyte by 504.3% in the 2nd quarter. Millennium Management LLC now owns 1,599,307 shares of the company's stock worth $7,677,000 after acquiring an additional 1,334,641 shares during the last quarter. Institutional investors own 44.71% of the company's stock.
Insider Buying and Selling
In related news, Director Brady W. Dougan sold 427,459 shares of the company's stock in a transaction dated Tuesday, November 19th. The stock was sold at an average price of $4.34, for a total transaction of $1,855,172.06. Following the transaction, the director now directly owns 1,992,253 shares of the company's stock, valued at $8,646,378.02. This represents a 17.67 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this link. Also, CEO Laura E. Niklason sold 261,369 shares of the company's stock in a transaction dated Wednesday, November 20th. The shares were sold at an average price of $4.40, for a total value of $1,150,023.60. Following the transaction, the chief executive officer now directly owns 1,730,884 shares in the company, valued at $7,615,889.60. This represents a 13.12 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 1,500,000 shares of company stock worth $6,606,799 in the last three months. 11.20% of the stock is owned by insiders.
Analysts Set New Price Targets
Several research firms have recently weighed in on HUMA. Benchmark boosted their target price on Humacyte from $15.00 to $17.00 and gave the company a "buy" rating in a research report on Monday, December 23rd. Piper Sandler set a $6.00 price objective on Humacyte and gave the company a "neutral" rating in a research report on Friday, October 18th. Cantor Fitzgerald reaffirmed an "overweight" rating and issued a $13.00 price objective on shares of Humacyte in a research report on Friday, September 20th. D. Boral Capital reaffirmed a "buy" rating and issued a $25.00 price objective on shares of Humacyte in a research report on Monday. Finally, HC Wainwright reiterated a "buy" rating and issued a $15.00 target price (up from $12.00) on shares of Humacyte in a report on Friday, December 20th. One analyst has rated the stock with a hold rating, six have assigned a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat.com, the stock presently has an average rating of "Buy" and a consensus price target of $13.71.
View Our Latest Stock Analysis on HUMA
Humacyte Stock Down 4.8 %
Shares of HUMA stock traded down $0.22 during mid-day trading on Monday, hitting $4.39. The stock had a trading volume of 2,870,027 shares, compared to its average volume of 3,627,962. The company has a debt-to-equity ratio of 0.61, a current ratio of 1.10 and a quick ratio of 1.10. The firm has a market capitalization of $552.52 million, a P/E ratio of -3.28 and a beta of 1.32. Humacyte, Inc. has a 12-month low of $2.48 and a 12-month high of $9.97. The firm's 50-day moving average is $4.67 and its two-hundred day moving average is $5.69.
About Humacyte
(
Free Report)
Humacyte, Inc engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs) to be implanted into patient without inducing a foreign body response or leading to immune rejection.
Featured Stories
Before you consider Humacyte, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Humacyte wasn't on the list.
While Humacyte currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
